Lenvatinib in combination with pembrolizumab is being developed as a first-line therapy for adults
with programmed death-ligand 1 (PD-L1) expressing recurrent or metastatic head and neck
squamous cell carcinoma (HNSCC). HNSCC is a cancer of the mouth, nose or throat that develops
in the squamous cells found in the outer layer of skin and the mucous membranes that line body
cavities. About a half of the patients with HNSCC have it return after treatment (recurrent) or it
spread to other parts of the body (metastatic). Recurrent/metastatic HNSCC is a difficult disease
to treat, with poor prognosis and survival rates.
Lenvatinib with pembrolizumab for the treatment of squamous cell carcinoma of the head and neck
Lenvatinib in combination with pembrolizumab is being developed as a first-line therapy for adults with programmed death-ligand 1 (PD-L1) expressing recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). HNSCC is a cancer of the mouth, nose or throat that develops in the squamous cells found in the outer layer of skin and the mucous membranes that line body cavities
Therapeutic Areas:
Head and Neck Cancer
Year:
2022